You are here

OxSodrol®

Recombinant copper-zinc Superoxide dismutase – (CuZnSOD) for prevention of pulmonary damage in neonates, licensed to Bio-Technology General, Inc., a subsidiary of Ferring Inc. The company completed a phase II clinical trial on use of CuZnSOD in treatment of bronchopulmonary dysplasia.